| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(6 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| US6235004 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
Norditropin Nordiflex is owned by Novo Nordisk Inc.
Norditropin Nordiflex contains Somatropin Recombinant.
Norditropin Nordiflex has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Norditropin Nordiflex are:
- US5849700
- US5849704
- US8841252
- US6004297
- US6235004
- USRE43834
- USRE41956
Norditropin Nordiflex was authorised for market use on 23 January, 2015.
Norditropin Nordiflex is available in injectable;injection dosage forms.
Norditropin Nordiflex can be used as the long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children.
The generics of Norditropin Nordiflex are possible to be released after 21 January, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE;INJECTION
NORDITROPIN NORDIFLEX family patents
